Enovis

Enovis shares trade at $18.17, a 52-week low, and are currently below InvestingPro’s fair-value estimate. Over the past year the price fell 42.24%, while the company reported adjusted earnings of $0.90 per share on revenue of $582.78 million for Q2 2026. Enovis announced the acquisition of eCential Robotics for about €176 million, which could create margin pressure and has prompted BMO and Citizens to cut their price targets. Analysts expect a return to profitability this year, but investors remain cautious due to the near-term outlook and cost pressures. » More on de.investing.com

Enovis presented a robotics focus at the Wells Fargo conference and announced a planned acquisition of Amplitude Surgical in Q4 2026 to combine shoulder and knee robotics with its ARVIS platform. Management reports normalized demand in the US and slower but above-market growth in Europe, where Enovis is gaining market share. The acquisition is expected to weigh on margins and leverage in the near term (EBITDA margin -100 basis points, leverage temporarily ~3.5x) but to drive growth and technology integration over the long term. Enovis is targeting a free cash flow conversion rate of ~50% next year (about $100 million) and 70–80% by 2029; the US launch of the knee robot is planned for 2028. » More on de.investing.com

Enovis shares hit a new 52-week low at $19.12, losing 18.65% just last week and down 39.14% year-to-date. Despite a surprising Q2 result (adjusted EPS $0.90 vs. $0.85 expected; revenue $582.78 million), a cautious outlook and ongoing cost pressures weigh on sentiment. Enovis announced the acquisition of eCential Robotics for about €176 million, prompting analysts to cut forecasts while largely maintaining positive ratings. Technical indicators on InvestingPro point to an oversold condition, which could present a contrarian buying opportunity. » More on de.investing.com

Enovis has made a binding offer to acquire eCential Robotics for an enterprise value of €155 million plus up to €35 million in milestone payments, with closing expected by end of 2026 and financed with cash and revolving-credit capacity. The deal brings eCential's robotics engineering, assembly and software into Enovis' ASTRA ecosystem and aims to launch a next-generation robotic platform for total knee procedures within two years, with initial commercial contribution expected in 2028 and a shoulder application to follow. Enovis expects the acquisition to temporarily dilute adjusted EBITDA margins by roughly 100 basis points in 2027 and to add about half a turn of leverage, while forecasting at least $100 million in free cash flow next year and margin improvements from growing robotics sales thereafter. The company will support eCential's existing spine agreements but will focus its own development on knee and shoulder applications and pursue a hybrid commercial model across distributors and corporate resources. » More on finance.yahoo.com

Enovis's stock rose about 11% after the Centers for Medicare & Medicaid Services withdrew announced reimbursement cuts for Enovis' non-invasive bone growth stimulators. The decision temporarily relieves regulatory pressure on the product segment and triggered the price move. » More on de.investing.com